Arena Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 75   

Articles published

ARNA 4.15 +0.03 (0.73%)
price chart
Belviq Sales Crack Critical Level
Sales of the anti-obesity Drug Belviq from Arena Pharmaceuticals (NASDAQ:ARNA) passed a critical level today with an improvement of 3.4% over the numbers last week.
Why Making Dramatic Moves : Barrick Gold (NYSE:ABX), Arena ...
On 1 Aug 2014 Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) provided a corporate update and reported financial results for the second quarter ended June 30, 2014.
Moving Stocks: Barrick Gold Corporation (NYSE:ABX), Ariad Pharmaceuticals ...  Markets Insider
Related articles »  
Big Movers: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), McDermott ...
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)'s shares closed at $4.12. The company on Aug. 1 provided a corporate update and reported financial results for the second quarter ended June 30, 2014.
Related articles »  
Arena Pharmaceuticals Falls on Wider-than-Expected Q2 Loss
Arena Pharmaceuticals, Inc. (ARNA - Snapshot Report) fell approximately 3.7% after the company reported a net loss (excluding one-time items) of 12 cents per share in the second quarter of 2014 wider than the Zacks Consensus Estimate of loss of 11 cents.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Dips As Loss Goes Beyond ...  FinancialsTrend
One-Time Stock Sale Boosts Arena To Profit (ARNA)  Seeking Alpha (registration)
Related articles »  
Hot Stocks: Zynga Inc(NASDAQ:ZNGA), Arena Pharmaceuticals, Inc.(NASDAQ ...
Zynga Inc(NASDAQ:ZNGA) gained one cent to move to a new closing price of $2.89, a 0.52% increase in value from the previous closing price.
Trading Volume Shifts: Image Sensing Systems, Inc.(NASDAQ:ISNS), Arena ...
Arena Pharmaceuticals, Inc.(NASDAQ:ARNA) gained seven cents to finish the day at a closing price of $4.25, a 1.67% increase in value from the previous closing price.
Related articles »  
Concerns on Biotech Stocks- Arena Pharmaceuticals, Inc. (NASDAQ:ARNA ...
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) [Trend Analysis] recently delivered Belviq sales of $3.5M (including $0.4 million from the 15-day free trial voucher redemption).
Related articles »  
Advertising And The Belviq Re-Launch
July of 2014 marked the "re-launch" of the anti-obesity drug Belviq from Arena Pharmaceuticals (NASDAQ:ARNA) and marketing partner Eisai (OTCPK:ESALY). Belviq had its initial launch in June of ... Needless to say, Arena stock suffered because sales ...
Related articles »  
Stock Runners: Arena Pharmaceuticals (NASDAQ:ARNA), AT&T, Inc. (NYSE:T ...
On 1 AUG Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) issued its quarterly earnings data on Friday. The company reported $0.03 earnings per share for the quarter, beating the analysts' consensus estimate of ($0.11) by $0.14.
Arena Pharmaceuticals' APD811 Granted Orphan Drug Status for Pulmonary ...
2, 2014 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that the US Food and Drug Administration (FDA) has granted orphan drug status to APD811 for the treatment of pulmonary arterial hypertension.
Related articles »